INT3731

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1977
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 17
Total Number 17
Disease Relevance 8.35
Pain Relevance 5.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

hydrolase activity, acting on glycosyl bonds (Neu1) plasma membrane (Neu1) lysosome (Neu1)
Anatomy Link Frequency
neuronal 1
myocardium 1
macrophages 1
Mouse 1
liver 1
Neu1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 20 99.56 Very High Very High Very High
Morphine 21 99.12 Very High Very High Very High
analgesia 12 98.72 Very High Very High Very High
opioid receptor 9 97.68 Very High Very High Very High
tolerance 12 96.96 Very High Very High Very High
Hyperalgesia 12 96.68 Very High Very High Very High
Opioid 9 95.76 Very High Very High Very High
addiction 5 91.16 High High
anesthesia 5 84.92 Quite High
cINOD 7 65.52 Quite High
Disease Link Frequency Relevance Heat
Cancer 169 100.00 Very High Very High Very High
Apoptosis 43 100.00 Very High Very High Very High
Targeted Disruption 9 99.96 Very High Very High Very High
Carcinoma 111 99.64 Very High Very High Very High
Gauchers Disease 16 99.64 Very High Very High Very High
INFLAMMATION 28 99.56 Very High Very High Very High
Hyperalgesia 15 98.68 Very High Very High Very High
Fabry Disease 32 98.20 Very High Very High Very High
Sprains And Strains 75 97.00 Very High Very High Very High
Pleurisy 2 95.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice.
Negative_regulation (inhibitor) of Neuraminidase associated with hyperalgesia, tolerance, opioid receptor, opioid and analgesia
1) Confidence 0.39 Published 2004 Journal Brain Res. Section Title Doc Link 14672816 Disease Relevance 0.46 Pain Relevance 1.53
These results provide the first evidence indicating that treatment with a neuraminidase inhibitor, oseltamivir, blocks morphine's hyperalgesic effects by decreasing neuronal levels of GM1.
Negative_regulation (inhibitor) of neuraminidase in neuronal associated with hyperalgesia and morphine
2) Confidence 0.39 Published 2004 Journal Brain Res. Section Abstract Doc Link 14672816 Disease Relevance 0.50 Pain Relevance 1.82
In this study, acute treatment of mice with the neuraminidase inhibitor, oseltamivir enhanced morphine analgesia.
Negative_regulation (inhibitor) of neuraminidase associated with analgesia and morphine
3) Confidence 0.39 Published 2004 Journal Brain Res. Section Abstract Doc Link 14672816 Disease Relevance 0.48 Pain Relevance 1.64
The neuraminidase inhibition titer was defined as the reciprocal serum dilution at which neuraminidase activity was 50% inhibited.


Negative_regulation (inhibited) of neuraminidase
4) Confidence 0.08 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2922371 Disease Relevance 0 Pain Relevance 0
For the subsequent neuraminidase inhibition studies, the concentration of the virus was adjusted to an equivalent of half-maximal neuraminidase activity.
Negative_regulation (equivalent) of neuraminidase
5) Confidence 0.08 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2922371 Disease Relevance 0 Pain Relevance 0
Effects of tamoxifen, celecoxib and the combination regimen on proliferation and apoptosis in neu-induced mammary carcinomas
Negative_regulation (apoptosis) of neu-induced associated with carcinoma and apoptosis
6) Confidence 0.06 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2374974 Disease Relevance 1.09 Pain Relevance 0
In contrast to our findings that celecoxib did not reduce tumor multiplicity of hormonally nonresponsive mammary carcinomas, tumor multiplicity was reduced by 41% in mouse mammary tumor virus-neu transgenic mice at a dose of 900 ppm [9].
Negative_regulation (reduced) of virus-neu associated with targeted disruption, cancer and carcinoma
7) Confidence 0.05 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2374974 Disease Relevance 1.91 Pain Relevance 0
This decrease in lysosomal enzyme activity can explain the accumulation of large residual bodies and interstitial material that occurs in the myocardium of the db+/db+ animals as part of the cardiomyopathy.
Negative_regulation (decrease) of lysosomal enzyme in myocardium associated with coronary heart disease
8) Confidence 0.04 Published 1980 Journal Lab. Invest. Section Abstract Doc Link 7421126 Disease Relevance 0.32 Pain Relevance 0.05
There is a progressive decrease in cardiac lysosomal enzyme activities of db+/db+ mice for the period 5 to 21 weeks of age.
Negative_regulation (decrease) of lysosomal enzyme
9) Confidence 0.03 Published 1980 Journal Lab. Invest. Section Abstract Doc Link 7421126 Disease Relevance 0.36 Pain Relevance 0.08
Inhibitors of the viral neuraminidase, oseltamivir and zanamivir [8] stop the efficient release of progeny virus from infected host cells, thus reducing cell-to-cell spread.
Negative_regulation (Inhibitors) of neuraminidase
10) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2964324 Disease Relevance 1.01 Pain Relevance 0
The agents which demonstrated potent anti-inflammatory action were found to inhibit acid lysosomal hydrolytic enzyme activities in mouse liver and macrophages at 10(-5) M concentrations.
Negative_regulation (inhibit) of lysosomal hydrolytic enzyme in macrophages associated with inflammation
11) Confidence 0.02 Published 1990 Journal Acta Pharm Nord Section Abstract Doc Link 2095797 Disease Relevance 0.65 Pain Relevance 0.21
In the presence of calcium the APN activity of the venom was also negligible, but the APL activity was reduced by 25% and some APB activity remained.
Negative_regulation (reduced) of APL
12) Confidence 0.01 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2919393 Disease Relevance 0 Pain Relevance 0
Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model

Gaucher disease type 1 is caused by the defective activity of the lysosomal enzyme, acid ?

Negative_regulation (defective) of lysosomal enzyme in Mouse associated with gauchers disease
13) Confidence 0.01 Published 2010 Journal PLoS ONE Section Title Doc Link PMC2873993 Disease Relevance 0.39 Pain Relevance 0
The agents which demonstrated potent anti-inflammatory action were found to inhibit acid lysosomal hydrolytic enzyme activities in mouse liver and macrophages at 10(-5) M concentrations.
Negative_regulation (inhibit) of lysosomal hydrolytic enzyme in liver associated with inflammation
14) Confidence 0.01 Published 1990 Journal Acta Pharm Nord Section Abstract Doc Link 2095797 Disease Relevance 0.65 Pain Relevance 0.21
Fabry disease (FD, OMIM 301500) is an X-linked inborn error of glycosphingolipid metabolism due to the deficient activity of alpha-galactosidase A, a lysosomal enzyme.
Negative_regulation (deficient) of lysosomal enzyme associated with fabry disease
15) Confidence 0.01 Published 2002 Journal BMC Med Genet Section Abstract Doc Link PMC134464 Disease Relevance 0.32 Pain Relevance 0
Nobiloside (127) inhibited neuraminidase from the bacterium Clostridium perfrigens with an IC50 of 0.5 ?
Negative_regulation (inhibited) of neuraminidase
16) Confidence 0.01 Published 2010 Journal Marine Drugs Section Body Doc Link PMC2852841 Disease Relevance 0.11 Pain Relevance 0
PGE1, PGE2, PGA1, PGA2, PGB1 and PGB2 reduced lysosomal enzyme release from cytochalasin B-treated neutrophils.
Negative_regulation (reduced) of lysosomal enzyme in neutrophils
17) Confidence 0.00 Published 1977 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 850132 Disease Relevance 0.07 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox